Loading...
•
Sep 30
Stryker Q3 2025 Earnings Report
Stryker reported strong third quarter 2025 results with double-digit adjusted earnings per share growth and robust sales across its segments.
Key Takeaways
Stryker delivered a strong third quarter in 2025, with consolidated net sales reaching $6.1 billion, an increase of 10.3%. The company achieved double-digit adjusted earnings per diluted share growth of 11.1% to $3.19, driven by strong execution and sustained demand across its broad portfolio.
Consolidated net sales increased by 10.3% to $6.1 billion in the third quarter of 2025.
Adjusted net earnings per diluted share grew by 11.1% to $3.19, demonstrating strong profitability.
MedSurg and Neurotechnology segment sales rose by 14.4% to $3.8 billion, while Orthopaedics sales increased by 3.9% to $2.3 billion.
Stryker raised its full-year 2025 guidance for organic net sales growth and adjusted net earnings per diluted share, reflecting confidence in continued momentum.
Stryker
Stryker
Stryker Revenue by Segment
Revenue by Segment
MedSurg and Neurotechnology Revenue
CapyFin.comOrthopaedics Revenue
CapyFin.com Forward Guidance
Stryker is raising its full-year 2025 guidance, expecting organic net sales growth of 9.8% to 10.2% and adjusted net earnings per diluted share in the range of $13.50 to $13.60, reflecting strong sales momentum and commitment to margin expansion.
Positive Outlook
- Raised full-year 2025 guidance for organic net sales growth to 9.8% to 10.2%.
- Raised full-year 2025 guidance for adjusted net earnings per diluted share to $13.50 to $13.60.
- Anticipates a modestly favorable pricing impact on sales.
- Expects a slightly positive impact from foreign exchange on both sales and adjusted net earnings per diluted share.
- Driven by sustained demand for products and commitment to margin expansion.
Challenges Ahead
- Unable to present a quantitative reconciliation for organic net sales growth due to unpredictability of acquisitions, divestitures, and foreign currency exchange rates.
- Unable to present a quantitative reconciliation for adjusted net earnings per diluted share due to unpredictability of structural optimization charges, acquisition-related expenses, and regulatory/legal/tax matters.
- The financial impact of certain items is uncertain and could be material to consolidated statements of earnings.
- Forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.
- Risks include weakening economic conditions, geopolitical risks, pricing pressures, and supply chain disruptions.
Revenue & Expenses
Visualization of income flow from segment revenue to net income